Novartis has reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two Phase III studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These pivotal studies enrolled more than 1,800 patients with neovascular age-related macular degeneration (nAMD) across 400 centres worldwide.
No Dia Mundial da Retina, sábado, 30 de setembro de 2017, a Retina Internacional, a Retina Brasil e outras 40 organizações associadas, estão lançando o ALERTA DAS DOENÇAS OCULARES RARAS para as entidades a ela ligadas, de caráter nacional ou regional.
Entendemos que chegou a hora de lutar de forma efetiva para que haja acesso de todos aos serviços de genotipagem para doenças hereditárias da retina e para as doenças oculares raras.
DIAGNOSIS IS KEY!
Bpifrance and Foundation Fighting Blindness have launched SparingVision to develop vision-saving treatment for Inherited Retinal Diseases. The newly established French company, SparingVision has won the 2017 i-Lab Grand Prize recognizing new and innovative companies. The i-Lab competition is organized by the French Ministry of Higher Education, Research and Innovation and Bpifrance (BPI).
ProQR Therapeutics N.V. has announced that the company’s investigational drug QRX-411 has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of retinitis pigmentosa, including Usher syndrome, the subtype targeted by QRX-411. Usher syndrome is the leading cause of combined deafness and blindness due to genetic defects in the Usher gene.
Report by Fraser Alexander, Local Organising Committee
On behalf of Retina International and the Local Organising committee for Retina 2018 New Zealand, I welcome you to the 20th Retina International world congress – to be held in New Zealand for the first time on February 10 and 11, 2018.
Retina International, formerly the International Retinitis Pigmentosa Association (IRPA), is a voluntary, charitable “umbrella association of national societies each of which is formed by people with a Retinal Dystrophy such as Retinitis Pigmentosa (RP), Usher Syndrome, Macular Degeneration (MD) and other allied retinal dystrophies, their families and friends.”
NOTE: The laws of some countries do not allow for charitable status; in such cases it must be clear that the society has charitable purposes and is not run for profit